2007
Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen
Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clinical Cancer Research 2007, 13: 228-233. PMID: 17200359, DOI: 10.1158/1078-0432.ccr-06-1345.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptorPathologic CR rateEpidermal growth factor receptorConcurrent trastuzumabGrowth factor receptorCR rateEfficacy dataBreast cancerStudy populationHigher pathologic complete remission rateSecond cohortPathologic complete remission rateCardiac safety dataCycles of FECCycles of paclitaxelOperable breast cancerComplete remission rateDisease-free survivalFactor receptorBreast cancer patientsNew safety concernsSame chemotherapyWeekly trastuzumabCyclophosphamide chemotherapyNeoadjuvant therapy
2006
Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy
Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M. Kinetics of serum HER‐2/neu changes in patients with HER‐2‐positive primary breast cancer after initiation of primary chemotherapy. Cancer 2006, 109: 496-501. PMID: 17149760, DOI: 10.1002/cncr.22418.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularCyclophosphamideEpirubicinFemaleFluorouracilHumansKineticsMiddle AgedNeoadjuvant TherapyPrognosisProspective StudiesReceptor, ErbB-2TrastuzumabConceptsPrimary breast cancerPathological complete responseBreast cancerECD levelsPrimary chemotherapyNeoadjuvant therapyPathological responseWeek 6HER-2 extracellular domainWeek 3HER-2/neu receptorCycles of fluorouracilCycles of paclitaxelNeu extracellular domainTrastuzumab-based regimensUtility of quantitationInitiation of chemotherapyExtracellular domainSame chemotherapyWeekly trastuzumabInitial chemotherapyNeoadjuvant chemotherapyComplete responseTreatment regimenResidual disease
2005
Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma
Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P‐glycoprotein inhibitor, in patients with chemotherapy‐resistant, advanced breast carcinoma. Cancer 2005, 104: 682-691. PMID: 15986399, DOI: 10.1002/cncr.21227.Peer-Reviewed Original ResearchConceptsAdministration of tariquidarP-gp expressionSestamibi scanBreast carcinomaSestamibi uptakeP-gp-positive tumorsTaxane-containing chemotherapy regimensDocetaxel-related toxicitiesLimited clinical activityObjective tumor responsePercent of patientsPhase II studyAdvanced breast carcinomaP-glycoprotein inhibitor tariquidarP-glycoprotein inhibitorsMultidrug resistance modulationP-gp transporterMultidrug resistance inhibitorsSame chemotherapyStable diseaseChemotherapy regimenChemotherapy regimensTaxane chemotherapyClinical responseDose modificationSignificantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer. Journal Of Clinical Oncology 2005, 23: 3676-3685. PMID: 15738535, DOI: 10.1200/jco.2005.07.032.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideDisease-Free SurvivalEpirubicinFemaleFluorouracilHumansMiddle AgedNeoadjuvant TherapyPaclitaxelProspective StudiesReceptor, ErbB-2Remission InductionTrastuzumabConceptsClinical congestive heart failureHuman epidermal growth factor receptorOperable breast cancerAddition of trastuzumabCongestive heart failureChemotherapy armData monitoring committeeEpidermal growth factor receptorGrowth factor receptorHeart failureBreast cancerHigher pathologic complete remission ratePathologic complete remission ratePathologic complete response rateCycles of fluorouracilCycles of paclitaxelHER2-positive diseaseComplete response rateComplete remission rateFactor receptorCardiac ejection fractionNeoadjuvant settingSame chemotherapyWeekly trastuzumabNeoadjuvant therapy